These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
321 related articles for article (PubMed ID: 36613613)
21. Consensus and guidelines on lipoprotein(a) - seeing the forest through the trees. Kronenberg F; Mora S; Stroes ESG Curr Opin Lipidol; 2022 Dec; 33(6):342-352. PubMed ID: 36251423 [TBL] [Abstract][Full Text] [Related]
22. Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society. Kronenberg F; Mora S; Stroes ESG; Ference BA; Arsenault BJ; Berglund L; Dweck MR; Koschinsky ML; Lambert G; Mach F; McNeal CJ; Moriarty PM; Natarajan P; Nordestgaard BG; Parhofer KG; Virani SS; von Eckardstein A; Watts GF; Stock JK; Ray KK; Tokgözoğlu LS; Catapano AL Atherosclerosis; 2023 Jun; 374():107-120. PubMed ID: 37188555 [TBL] [Abstract][Full Text] [Related]
23. Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review. Duarte Lau F; Giugliano RP JAMA Cardiol; 2022 Jul; 7(7):760-769. PubMed ID: 35583875 [TBL] [Abstract][Full Text] [Related]
24. Role of lipoprotein (a) and LPA KIV2 repeat polymorphism in bicuspid aortic valve stenosis and calcification: a proof of concept study. Sticchi E; Giusti B; Cordisco A; Gori AM; Sereni A; Sofi F; Mori F; Colonna S; Fugazzaro MP; Pepe G; Nistri S; Marcucci R Intern Emerg Med; 2019 Jan; 14(1):45-50. PubMed ID: 30099661 [TBL] [Abstract][Full Text] [Related]
25. Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels. Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Hohenstein B; Roeseler E; Heigl F; Grützmacher P; Blume H; Klingel R; Vogt A; Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):33-38. PubMed ID: 30838552 [TBL] [Abstract][Full Text] [Related]
26. Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases. Kronenberg F Cardiovasc Drugs Ther; 2016 Feb; 30(1):87-100. PubMed ID: 26896185 [TBL] [Abstract][Full Text] [Related]
27. The re-emergence of lipoprotein(a) in a broader clinical arena. Tsimikas S Prog Cardiovasc Dis; 2016; 59(2):135-144. PubMed ID: 27497506 [TBL] [Abstract][Full Text] [Related]
29. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. Tsimikas S; Hall JL J Am Coll Cardiol; 2012 Aug; 60(8):716-21. PubMed ID: 22898069 [TBL] [Abstract][Full Text] [Related]
30. Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia. Vuorio A; Watts GF; Kovanen PT Atherosclerosis; 2019 Feb; 281():25-30. PubMed ID: 30616181 [TBL] [Abstract][Full Text] [Related]
31. An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial. Bergmark BA; O'Donoghue ML; Murphy SA; Kuder JF; Ezhov MV; Ceška R; Gouni-Berthold I; Jensen HK; Tokgozoglu SL; Mach F; Huber K; Gaciong Z; Lewis BS; Schiele F; Jukema JW; Pedersen TR; Giugliano RP; Sabatine MS JAMA Cardiol; 2020 Jun; 5(6):709-713. PubMed ID: 32347887 [TBL] [Abstract][Full Text] [Related]
32. A Replicated, Genome-Wide Significant Association of Aortic Stenosis With a Genetic Variant for Lipoprotein(a): Meta-Analysis of Published and Novel Data. Cairns BJ; Coffey S; Travis RC; Prendergast B; Green J; Engert JC; Lathrop M; Thanassoulis G; Clarke R Circulation; 2017 Mar; 135(12):1181-1183. PubMed ID: 28320808 [No Abstract] [Full Text] [Related]
33. Daring to dream: Targeting lipoprotein(a) as a causal and risk-enhancing factor. Koschinsky ML; Stroes ESG; Kronenberg F Pharmacol Res; 2023 Aug; 194():106843. PubMed ID: 37406784 [TBL] [Abstract][Full Text] [Related]
34. Current and future role of lipoprotein(a) in preventive cardiology. Berman AN; Blankstein R Curr Opin Cardiol; 2019 Sep; 34(5):514-518. PubMed ID: 31261178 [TBL] [Abstract][Full Text] [Related]
35. Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort. Arsenault BJ; Boekholdt SM; Dubé MP; Rhéaume E; Wareham NJ; Khaw KT; Sandhu MS; Tardif JC Circ Cardiovasc Genet; 2014 Jun; 7(3):304-10. PubMed ID: 24704946 [TBL] [Abstract][Full Text] [Related]
36. Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic Stenosis. Yeang C; Cotter B; Tsimikas S Cardiovasc Drugs Ther; 2016 Feb; 30(1):75-85. PubMed ID: 26780907 [TBL] [Abstract][Full Text] [Related]
37. Lp(a) and cardiovascular risk: Investigating the hidden side of the moon. Bucci M; Tana C; Giamberardino MA; Cipollone F Nutr Metab Cardiovasc Dis; 2016 Nov; 26(11):980-986. PubMed ID: 27514608 [TBL] [Abstract][Full Text] [Related]
38. Genetic associations with valvular calcification and aortic stenosis. Thanassoulis G; Campbell CY; Owens DS; Smith JG; Smith AV; Peloso GM; Kerr KF; Pechlivanis S; Budoff MJ; Harris TB; Malhotra R; O'Brien KD; Kamstrup PR; Nordestgaard BG; Tybjaerg-Hansen A; Allison MA; Aspelund T; Criqui MH; Heckbert SR; Hwang SJ; Liu Y; Sjogren M; van der Pals J; Kälsch H; Mühleisen TW; Nöthen MM; Cupples LA; Caslake M; Di Angelantonio E; Danesh J; Rotter JI; Sigurdsson S; Wong Q; Erbel R; Kathiresan S; Melander O; Gudnason V; O'Donnell CJ; Post WS; N Engl J Med; 2013 Feb; 368(6):503-12. PubMed ID: 23388002 [TBL] [Abstract][Full Text] [Related]